Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
30 June 2020Website:
http://www.aditxt.comNext earnings report:
N/ALast dividends:
N/ANext dividends:
N/APrice
pre-market | 12 min agoDividend
Analysts recommendations
Institutional Ownership
ADTX Latest News
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, July 02, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, announces that it has entered into an amending agreement (the “Amending Agreement”) among the Company, Aditxt, Inc. (“Aditxt”) and Adivir, Inc. (“Adivir” and together with the Company and Aditxt, the “Parties”) to amend the previously announced arrangement agreement dated April 1, 2024 among the Parties (the “Arrangement Agreement”), pursuant to which Aditxt, through its wholly-owned subsidiary, Adivir, will acquire all of the issued and outstanding Class A common shares of the Company by way of a court-approved plan of arrangement under the Canada Business Corporations Act (the “Transaction”). For further information on the Transaction please see the Company's news release dated April 2, 2024, which is available on the Company's profile on SEDAR+ at www.sedarplus.ca.
Aditxt Inc's shares fell more than 20% in Tuesday premarket trading after the company announced the pricing of a $6 million private placement of shares and accompanying warrants. The Richmond, Virginia-based medical technologies company said it entered definitive agreements for the purchase and sale of an aggregate of 1,237,114 shares of common stock at $4.85 per share and accompanying warrant, in a private placement priced at the market under Nasdaq rules.
Aditxt (NASDAQ: ADTX ) stock is rallying higher on Tuesday after the biotech company announced its plan to acquire Evofem Biosciences (OTCMKTS: EVFM ). According to a press release, Aditxt has agreed to acquire Evofem Biosciences in a deal worth $100 million.
The Aditxt (NASDAQ: ADTX) stock price jumped by more than 83% on Tuesday, making it one of the best performers in Wall Street. The shares surged to a high of $9.47, its highest point since October 19th.
Aditxt (NASDAQ: ADTX ) stock is rocketing higher on Thursday despite a lack of news from the biotechnology company. There are no new press releases or filings with the Securities and Exchange Commission (SEC) that explain why ADTX stock is up today.
RICHMOND, Va. & MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- #autoimmunity--Aditxt,® Inc, (NASDAQ: ADTX) (“Aditxt” or the “Company”), a global innovation company focused on developing and commercializing technologies that monitor and modulate the immune system, today announced that the Aditxt management team will participate in the H.C. Wainwright 25th Annual Global Investment Conference being held September 11th -13th, 2023, in New York City. The in-person venue for the event is the Lotte New York Palace Hotel in.
Aditxt (NASDAQ: ADTX) stock price has been in the spotlight in the past few days. The shares plunged by more than 24% on Friday, one of its worst days this year.
Penny stocks to buy for under $1 but are they worth the risk? The post 7 Hot Penny Stocks Under $1.10 To Watch This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Penny stocks to watch this week. The post Best Penny Stocks To Buy?
What type of business is Aditxt?
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
What sector is Aditxt in?
Aditxt is in the Healthcare sector
What industry is Aditxt in?
Aditxt is in the Biotechnology industry
What country is Aditxt from?
Aditxt is headquartered in United States
When did Aditxt go public?
Aditxt initial public offering (IPO) was on 30 June 2020
What is Aditxt website?
https://www.aditxt.com
Is Aditxt in the S&P 500?
No, Aditxt is not included in the S&P 500 index
Is Aditxt in the NASDAQ 100?
No, Aditxt is not included in the NASDAQ 100 index
Is Aditxt in the Dow Jones?
No, Aditxt is not included in the Dow Jones index
When does Aditxt report earnings?
Next earnings report date is not announced yet